Healthcare Medical Devices Biotechnology

Viscosupplementation Market

Global Industry Analysis and Forecast 2024-2031

Pages : 120

Base Year : 2023

Released Year : May 2024

Format :Pdf Ppt Xls

Report ID:KR692

Author : Siddhi J.

Snapshot Icons

Base Year

2023

Snapshot Icons

Forecast Year

2024-2031

Snapshot Icons

Historical Years

2019-2022

Snapshot Icons

Market Value (2023)

USD 3275.4 Million

Snapshot Icons

Forecasted Value (2031)

USD 5938.3 Million

Snapshot Icons

CAGR (2024 - 2031)

7.91%

Snapshot Icons

Fastest Growing Region (2024 - 2031)

Europe

Snapshot Icons

Largest Region

Asia Pacific

Snapshot Icons

By Product

Single Injection, Three Injection, Five Injection

Snapshot Icons

By End-user

Orthopedic Clinics/ASCs, Hospitals


Viscosupplementation Market Size

The global Viscosupplementation Market size was valued at USD 3275.4 million in 2023 and is projected to reach USD 5938.3 million by 2031, growing at a CAGR of 7.91% from 2024 to 2031. The rising emphasis on expanding into new markets, particularly in emerging economies experiencing a rise in the prevalence of joint diseases, is expected to drive market growth. The rising prevalence of osteoarthritis, particularly among the aging population. Increasing awareness about minimally invasive treatment options for joint pain, coupled with advancements in hyaluronic acid-based products, further propels market growth. Additionally, the growing preference for non-surgical interventions and the expanding healthcare infrastructure in emerging economies contribute to the increased adoption of viscosupplementation treatments.

The growth of the viscosupplementation market is driven by several factors, including knee pain, the aging population, and the growing incidence of osteoarthritis globally. Technological advancements in the healthcare industry are further driving market growth. These advancements are contributing to the enhancement of the product and creating awareness among individuals, thereby boosting the production of viscosupplments. However, challenges such as the high cost of products, and recalls are expected to hinder market growth. Moreover,  emerging trends such as the introduction of single-injection viscosupplements for improved patient compliance, the integration of hyaluronic acid-based viscosupplements with biologics, and the adoption of personalized medicine approaches are expected to create new opportunities for revenue generation. Strategic collaborations between pharmaceutical companies and healthcare providers are further contributing to the potential for innovation and market expansion.

Viscosupplementation involves the replacement of synovial fluid in joints with a hyaluronate solution possessing viscous properties similar to the natural synovial fluid. Viscosupplementation is primarily used for the management of osteoarthritis in joints such as the knee, hip, or shoulder. Hyaluronic acid, the main component of viscosupplements, is a naturally occurring substance found in joint fluid and cartilage. It helps cushion and lubricate the joints, providing relief from pain and stiffness associated with osteoarthritis. The procedure involves injecting the viscosupplement directly into the affected joint under sterile conditions, often performed by a trained healthcare provider. Multiple injections may be required over a specified treatment regimen to achieve optimal results. Viscosupplementation is considered a minimally invasive treatment option for osteoarthritis and is typically recommended for patients who have not responded well to conventional therapies like pain medications or physical therapy. The market encompasses various stakeholders, including pharmaceutical companies, medical device manufacturers,and healthcare providers seeking relief from osteoarthritis-related discomfort.

Analyst’s Review 

The viscosupplementation market is expected to witness significant growth in the foreseeable future. Leading companies operating in the market are investing heavily in innovative formulations and delivery mechanisms to address the evolving needs of patients and healthcare providers. Such strategic alliances facilitate access to new markets, technologies, and expertise, thereby strengthening their competitive position in the global marketplace.

Viscosupplementation Market Growth Factors

The growing incidence of osteoarthritis (OA) is a significant factor fueling the growth of the viscosupplementation market. Osteoarthritis (OA) is a chronic disease that predominantly affects individuals aged 30 and above. It has the potential to progress to a disabling condition, imposing substantial burdens on both affected individuals and healthcare systems. For instance, according to HealthData, it is projected that by 2050, 1 million people will be living with Osteoarthritis (OA), significantly impacting the individual’s lifestyle. The surge in OA cases underlines the pressing need for the development and implementation of effective treatment methods, such as viscosupplementation. 

The expansion of the viscosupplementation market is propelled by the rise in chronic disease, the growing aging population, and sedentary lifestyle leading to conditions such as diabetes, which in turn contribute to the prevalence of osteoarthritis (OA), among others. However, challenges such as the high cost of the products and reimbursement policies surrounding the drug approval are anticipated to hinder market growth. To overcome these challenges, key manufacturers are focusing on creating innovative products to gain a competitive edge in the global market. Moreover, favorable government initiatives and growing awareness regarding the treatment of osteoarthritis (OA) are foreseen to propel market growth.

Viscosupplementation Market Trends

The growing trend of non-surgical procedures is contributing significantly to viscosupplementation market development. Viscosupplementation is considered to be a minimally invasive process, making it a viable method for patients. The demand for non-surgical treatments for osteoarthritis is increasing, fueled by patients' preferences for minimally invasive interventions and their desire to avoid the risks and lengthy recovery associated with surgery. Moreover, advancements in the development of therapies utilizing hyaluronic acid, a key component of viscosupplements, are fueling market growth. Additionally, existing viscosupplements have consistently demonstrated clinical effectiveness, thereby establishing themselves as the most efficient treatment option for knee osteoarthritis.

The mounting demand for hyaluronic acid-based viscosupplementation therapy is backed by the increasing focus on personalized medicine and tailored treatment approaches. Healthcare providers are recognizing the importance of individualized care based on factors, such as patient age, severity of joint disease, comorbidities, and lifestyle factors. This trend is driving the development of customized viscosupplementation regimens, where treatment protocols are adapted to meet the specific needs and preferences of each patient. Personalized medicine enhances therapeutic outcomes while improving patient satisfaction and adherence to treatment plans. Additionally, advancements in biomarker research and diagnostic imaging techniques are facilitating a more accurate disease characterization and treatment response prediction, which is supporting the shift toward personalized viscosupplementation therapies. As healthcare evolve toward a patient-centric approach, the demand for personalized viscosupplementation is expected to grow, establishing itas a standard of care for managing  joint diseases.

Segmentation Analysis

The global viscosupplementation market is segmented based on product, end-user, and region.

By Product

Based on product, the market is segmented into single injection, three injection, and five injection. The three injection segment led the market in 2023, reaching a valuation of USD 1409.6 million. The growing preference for three-injection procedures in osteoarthritis treatment is expected to drive the growth of the segment. These procedures are widely used by medical professionals in total knee replacement surgery due to their efficacy.

Three-injection procedures are the most preferred method to treat osteoarthritis due to their effectiveness. Medical practitioners generally prefer three injections to help avoid total knee replacement surgery in cases of osteoarthritis. This, along with investments in R&D and the growing need to treat the ailment, is anticipated to drive market growth over the forecast period. The continuous advancements in medical technology and the increasing focus on non-invasive treatments further support the demand for three-injection procedures, making them a significant factor in the osteoarthritis treatment landscape. Additionally, the approval and positive outcomes of numerous clinical trials confirm the efficacy of these procedures in the treatment of osteoarthritis. Furthermore, increased investments in research and development, leading to product development, are expected to create a favorable environment for market growth over the forecast period. As the demand for effective osteoarthritis treatments continues to rise, the need for three-injection procedures is expected to surge, thereby fostering growth and innovation within the market.

By End-User

Based on end-user, the market is classified into orthopedic clinics/ASCs and hospitals. The orthopedic clinics/ASCs segment secured the largest revenue share of 65.59% in 2023. The segment is projected to experience robust growth due to the rise of ambulatory surgical centers (ASCs) in healthcare delivery. These ASCs offer efficient outpatient surgical care, encompassing diagnostic and preventative procedures. ASCs provide a range of surgical procedures, including knee replacement, ACL surgery, hip replacement, shoulder replacement, and others, all performed within a single day. These procedures are often less invasive and require minimal or no hospitalization, reducing healthcare costs and patient inconvenience. Furthermore, orthopedic clinics play a pivotal role in addressing musculoskeletal issues, focusing on both surgical and non-surgical interventions for joint, bone, ligament, muscle, and nerve-related ailments across the body. As the aging population is witnessing a surge in osteoarthritis cases, the demand for orthopedic services, particularly those offered at ASCs, is anticipated to increase. The convenience, efficiency, and specialized care provided by ASC are expected to further support the growth of the segment.

Viscosupplementation Market Regional Analysis

Based on region, the global enteral feeding devices market is classified into North America, Europe, Asia-Pacific, MEA, and Latin America.

Viscosupplementation Market Size & Share, By Region, 2024-2031

Asia-Pacific emerged as the leading region in the viscosupplementation market in 2023, attaining a valuation of USD 1477.9 million. Factors such as the aging population, lifestyle diseases, and improved healthcare infrastructure have contributed to the rising prevalence of knee osteoarthritis, which is contributing to regional market growth. As a result, there has been an increased adoption of viscosupplementation as a non-surgical treatment option. Countries such as China, India, Japan, and South Korea have been experiencing strong demand for viscosupplements. Additionally, economic development in emerging nations, coupled with the growth of medical tourism, is anticipated to fuel regional market expansion. Additionally, the presence of leading manufacturers in the region, especially in China, is developing cost-effective viscosupplements to meet rising domestic demand. This localization production addresses the needs of the local market while also bolstering the continuous growth of the Asia-Pacific viscosupplementation industry.

Europe is likely to experience significant growth at a CAGR of 9.26% over 2024-2031. The regional market is expected to witness a notable shift from multiple-injection cycle products to single-injection treatments, driven by the convenience factor associated with the treatment. Single-injection treatments offer greater ease of administration and improved patient compliance, factors that are pivotal for both healthcare providers and patients. Moreover, the relative cost-benefit advantage of single-injection treatments is expected to foster their adoption in the region over the forecast period. In addition, various regional organizations, such as the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), play a crucial role in addressing the prevalence of osteoarthritis and osteoporosis. The ESCEO is a valuable platform for disseminating current clinical and economic information to practitioners. It further facilitates collaboration and interaction among clinical scientists, pharmaceutical industry stakeholders, and regulators, thereby contributing to regional market growth. 

Competitive Landscape

The global viscosupplementation market report will provide valuable insight with an emphasis on the fragmented nature of the industry. Prominent players are focusing on several key business strategies such as partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their market shares across different regions. Strategic initiatives, including investments in R&D activities, the establishment of new manufacturing facilities, and supply chain optimization, could create new opportunities for market growth.

List of Key Companies in Viscosupplementation Market

  • Sanofi S.A.
  • Zimmer Biomet
  • Bioventus
  • Anika Therapeutics Inc.
  • Fidia Farmaceutici S.p.A.
  • Ferring B.V.
  • Seikagaku Corporation
  • Johnson & Johnson Medtech
  • OrthogenRx, Inc.
  • Chugai Pharmaceutical Co., Ltd.

Key Industry Developments 

  • April 2022 (Funding): Carthroni X, Inc. secured funding for CX-011, an injectable therapeutic targeting knee osteoarthritis progression. This funding highlights the company's dedication to addressing the pressing medical needs of knee osteoarthritis patients and provides the resources needed to advance CX-011 through crucial development stages.
  • May 2023 (Acqusition): Abiogen Pharma S.p.A., a leading Italian company specializing in osteoarticular and bone metabolism disorders, announced its acquisition of a 97.09% stake in EffRx Pharmaceuticals SA., headquartered in Switzerland, The company is dedicated to developing and distributing prescription medications designed for musculoskeletal and rare diseases across European and global markets. This acquisition underscores Abiogen Pharma's strategic commitment to broadening its portfolio and presence within the musculoskeletal treatment sector. It further establishes Abiogen Pharma as a frontrunner in the industry, poised to address a wider range of medical needs and extend its reach across diverse markets.

The Global Viscosupplementation Market is Segmented as:

By Product

  • Single Injection
  • Three Injection
  • Five Injection

By End-user

  • Orthopedic Clinics/ASCs
  • Hospitals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • U.K.
    • Spain
    • Germany
    • Italy
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • North Africa
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
CHOOSE LICENCE TYPE
CUSTOMIZATION OFFERED
  • Check Icon Additional Company Profiles
  • Check Icon Additional Countries
  • Check Icon Cross Segment Analysis
  • Check Icon Regional Market Dynamics
  • Check Icon Country-Level Trend Analysis
  • Check Icon Competitive Landscape Customization
  • Check Icon Extended Forecast Years
  • Check Icon Historical Data Up to 5 Years
Frequently Asked Questions (FAQ's)
The global market is projected to reach USD 5938.3 million by 2031, growing at a CAGR of 7.91% from 2024 to 2031.
The global market was valued at USD 3275.4 million in 2023.
Growing prevalence of OA is expected to drive the market growth.
Top manufacturers of enteral feeding devices market are Sanofi S.A., Zimmer Biomet, Bioventus, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Johnson & Johnson Medtech, OrthogenRx, Inc., Chugai Pharmaceutical Co., Ltd., and others.
Europe is the fastest growing region with the CAGR of 9.26% in the forecasted period (2024-2031) with the market value forecasted to reach at USD 1487.5 million.
By product, three injection will hold the maximum share in the viscosupplementation market with the revenue value of USD 2566.5 Million in 2031.
Get the latest!

Get actionable strategies to empower your business and market domination

  • Deliver Revenue Impact
  • Demand Supply Patterns
  • Market Estimation
  • Real-Time Insights
  • Market Intelligence
  • Lucrative Growth Opportunities
  • Micro & Macro Economic Factors
  • Futuristic Market Solutions
  • Revenue-Driven Results
  • Innovative Thought Leadership